Skip to content
Screener

Intellia Therapeutics NTLA Q1 2026 earnings

Reported May 11, 2026 · Before market open

Revenue$15.0MBeat by $1.2M
EPS-$0.81Beat by $0.11
Revenue estimate$13.8M
EPS estimate-$0.92

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$9.7M
EPS estimate-$0.82

Financials

Q1 2026

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.51B+106%
Enterprise value$1.46B+100%
P/S22.9×+6.8×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

FAQ

When did Intellia Therapeutics report Q1 2026 earnings?
Intellia Therapeutics (NTLA) reported Q1 2026 earnings on May 11, 2026 before market open.
What were Intellia Therapeutics's Q1 2026 revenue and EPS?
Intellia Therapeutics reported revenue of $15.0M and eps of $-0.81 for Q1 2026.
Did Intellia Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $13.8M by $1.2M. EPS beat the consensus estimate of $-0.92 by $0.11.
How did Intellia Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 9.5% from $16.6M a year earlier and eps grew 26.4% from $-1.10.
Where can I find Intellia Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-215721) and the 10-Q periodic report (0001193125-26-215740) directly on SEC EDGAR. The filing index links above go to sec.gov.